Blueprint Medicines Corp’s recently made public that its Director Albers Jeffrey W. unloaded Company’s shares for reported $0.51 million on Nov 07 ’24. In the deal valued at $102.00 per share,5,000 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 157,557 shares worth roughly $13.97 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Albers Jeffrey W. bought 5,000 shares, generating $510,000 in total proceeds.
Before that, Namouni Fouad sold 3,633 shares. Blueprint Medicines Corp shares valued at $324,500 were divested by the PRESIDENT, R & D at a price of $89.32 per share. As a result of the transaction, Namouni Fouad now holds 69,070 shares, worth roughly $6.13 million.
JP Morgan initiated its Blueprint Medicines Corp [BPMC] rating to an Overweight in a research note published on November 14, 2024; the price target was $126. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Neutral”‘ rating. Stephens began covering BPMC with “an Overweight” recommendation on May 14, 2024. Leerink Partners revised its rating on May 06, 2024. It rated BPMC as “a Market perform” which previously was an “an Underperform”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -7.28% to $88.69. Over the last five days, the stock has lost -12.04%. Blueprint Medicines Corp shares have fallen nearly -3.85% since the year began. Nevertheless, the stocks have risen 39.30% over the past one year. While a 52-week high of $121.90 was reached on 07/16/24, a 52-week low of $62.56 was recorded on 02/14/24. SMA at 50 days reached $89.59, while 200 days put it at $95.66.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 85.95, which if violated will result in even more drops to 83.22. On the upside, there is a resistance level at 93.88. A further resistance level may holdings at 99.08. The Relative Strength Index (RSI) on the 14-day chart is 43.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.96%. Stochastics %K at 57.11% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2024-10-31, growing by 0.6 million shares to a total of 4.13 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.53 million shares. There was a rise of 14.62%, which implies that there is a positive sentiment for the stock.
